

# **Detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its first variants in fourplex real-time quantitative reverse transcription-PCR assays.**

Mathieu Durand<sup>2</sup>, Philippe Thibault<sup>2</sup>, Simon Lévesque<sup>3,4</sup>, Ariane Brault<sup>1</sup>, Alex Carignan<sup>3</sup>, Louis Valiquette<sup>3</sup>, Philippe Martin<sup>3</sup>, and Simon Labbé<sup>1\*</sup>

<sup>1</sup>Département de Biochimie et de Génomique Fonctionnelle, Faculté de médecine et des sciences de la santé, Université de Sherbrooke, Sherbrooke, QC, J1E 4K8, Canada.

<sup>2</sup>Plateforme RNomique et de Génomique Fonctionnelle, Université de Sherbrooke, Sherbrooke, QC, Canada.

<sup>3</sup>Département de Microbiologie et d'Infectiologie, Faculté de médecine et des sciences de la santé, Université de Sherbrooke, Sherbrooke, QC, J1E 4K8, Canada.

<sup>4</sup>Laboratoire de Microbiologie, Centre Intégré Universitaire de Santé et de Services Sociaux (CIUSSS) de l'Estrie, Centre Hospitalier Universitaire de Sherbrooke (CHUS), Sherbrooke, QC, J1H 5N4, Canada.

\*Corresponding author : Simon Labbé

E-mail: Simon.Labbe@USherbrooke.ca

## **TABLE OF CONTENT : Supplemental Figure 1.**

### **Legend**

**Fig. S1.** *Sequences of the synthetic oligomers used to create the indicated gBlocks.* Each targeted SARS-CoV-2 region from the Orflab, Spike, E (envelope), and N (nucleocapsid) genes (according to the Wuhan-Hu-1 genome reference sequence and mutant derivatives) were designed accompanied with a T7 promoter sequence (bold) at their 5' ends.

Supplemental Figure 1. Sets of oligonucleotide primers

-----  
Orflab forward and reverse (strain L)

5'-**TAATACGACTCACTATAGG**ATGGTGGTGTCACTCGTGACATAGCATCTACAGATACTGTTTTGCTAACAAACATGCTGATTTTGACACATGGTTAGCC  
AGCGTGGTGGTAGTTATACTAATGACAAAGCTTGCCATTGATTGCTGCAGTCATAACA-3'  
5'-TGTTATGACTGCAGCAATCAATGGGCAAGCTTTGTCATTAGTATAACTACCACCACGCTGGCTAAACCATGTGTCAAATCAGCATGTTTGTAGCAAAA  
CAAGTATCTGTAGATGCTATGTCACGAGTGACACCACCATCCTATAGTGAGTCGTATTA-3'

-----  
Orflab forward and reverse (strain S)

5'-**TAATACGACTCACTATAGG**ATGGTGGTGTCACTCGTGACATAGCATCTACAGATACTGTTTTGCTAACAAACATGCTGATTTTGACACATGGTTAGTC  
AGCGTGGTGGTAGTTATACTAATGACAAAGCTTGCCATTGATTGCTGCAGTCATAACA-3'  
5'-TGTTATGACTGCAGCAATCAATGGGCAAGCTTTGTCATTAGTATAACTACCACCACGCTGACTAAACCATGTGTCAAATCAGCATGTTTGTAGCAAAA  
CAAGTATCTGTAGATGCTATGTCACGAGTGACACCACCATCCTATAGTGAGTCGTATTA-3'

-----  
Spike D614 forward and reverse

5'-**TAATACGACTCACTATAGG**CTTGACATTACACCATGTTCTTTTGGTGGTGTCAAGTGTATAACACCAGGAACAAATACTTCTAACCAGGTTGCTGTTCTT  
TATCAGGATGTTAACTGCACAGAAGTCCCTGTTGCTATTTCATGCAGATCAACTTACTCCTACTTGGCGTGTATTCTACAGGTTCTAATGTTT-3'  
5'-AAACATTAGAACCCTGTAGAATAAACACGCCAAGTAGGAGTAAGTTGATCTGCATGAATAGCAACAGGGACTTCTGTGCAGTTAACATCCTGATAAAGAAC  
AGCAACCTGGTTAGAAGTATTTGTTCTCGTGTATAACACTGACACCACCAAAAGAACATGGTGTAAATGTCAAGCCTATAGTGAGTCGTATTA-3'

-----  
Spike 614G forward and reverse

5'-**TAATACGACTCACTATAGG**CTTGACATTACACCATGTTCTTTTGGTGGTGTCAAGTGTATAACACCAGGAACAAATACTTCTAACCAGGTTGCTGTTCTT  
TATCAGGATGTTAACTGCACAGAAGTCCCTGTTGCTATTTCATGCAGATCAACTTACTCCTACTTGGCGTGTATTCTACAGGTTCTAATGTTT-3'  
5'-AAACATTAGAACCCTGTAGAATAAACACGCCAAGTAGGAGTAAGTTGATCTGCATGAATAGCAACAGGGACTTCTGTGCAGTTAACACCTGATAAAGAAC  
AGCAACCTGGTTAGAAGTATTTGTTCTCGTGTATAACACTGACACCACCAAAAGAACATGGTGTAAATGTCAAGCCTATAGTGAGTCGTATTA-3'

-----  
Spike N501 forward and reverse

5'-**TAATACGACTCACTATAGG**AACCTTTTGGAGAGAGATATTTCAACTGAAATCTATCAGGCCGGTAGCACACCTTGAATGGTGTGAAGGTTTAAATGTT  
ACTTTCCTTTTACAATCATATGGTTTCCAACCCACTAATGGTGTGGTTACCAACCATACAGAGTAGTAGTACTTCTTTTGAACCTTCTACATGCACCAGCAAC  
TGTTTGTGGACC  
5'-GGTCCACAACAGTTGCTGGTGCATGTAGAAGTTCAAAGAAAGTACTACTACTCTGTATGGTTGGTAACCAACACCATAGTGGGTTGGAACCATATG  
ATTGTAAAGGAAAGTAAACAATTAACACCTTCAACACCATTACAAGGTGTCTACCGCCTGATAGATTTTCAAGTTGAAATATCTCTCTCAAAGGTTCTCTATAG  
TGAGTCGTATTA-3'

-----  
Spike 501Y forward and reverse

5'-**TAATACGACTCACTATAGG**AACCTTTTGGAGAGAGATATTTCAACTGAAATCTATCAGGCCGGTAGCACACCTTGAATGGTGTGAAGGTTTAAATGTT  
ACTTTCCTTTTACAATCATATGGTTTCCAACCCACTAATGGTGTGGTTACCAACCATACAGAGTAGTAGTACTTCTTTTGAACCTTCTACATGCACCAGCAAC  
TGTTTGTGGACC  
5'-GGTCCACAACAGTTGCTGGTGCATGTAGAAGTTCAAAGAAAGTACTACTACTCTGTATGGTTGGTAACCAACACCATAGTGGGTTGGAACCATATG  
ATTGTAAAGGAAAGTAAACAATTAACACCTTCAACACCATTACAAGGTGTCTACCGCCTGATAGATTTTCAAGTTGAAATATCTCTCTCAAAGGTTCTCTATAG  
TGAGTCGTATTA-3'

-----  
E Sarbeco forward and reverse

5'-**TAATACGACTCACTATAGG**ATGTAATCTGTTTTCGGAAGAGACAGGTACGTTAATAGTTAATAGCGTACTTCTTTTTCTTGTCTTTCGTTGATTCTTG  
CTAGTTACTACTAGCCATCCTTACTGCGCTTCGATTGTGTGCGTACTGCTGCAATATTTGTTAACGTGAGTCTTGTAAAACCTTCTTTTTACGTTTACTCTCGTG  
TAAAAATCTGAATTTCTTAGAGTTCCTGATCTTCTGGTCTAA-3'  
5'-TTAGACCAGAAGATCAGGAACCTTAGAAGAATTCAGATTTTTAACACGAGAGTAAACGTAAAAAGAAGGTTTTACAAGACTCACGTTAACAAATATTGCAG  
CAGTACGCACAAATCGAAGCGCAGTAGGATGGCTAGTGAATAGCAAGAATACCACGAAAGCAAGAAAAGAAGTACGCTATTAACATTAACGTACCTG  
TCTCTTCGAAACGAATGAGTACATCCTATAGTGAGTCGTATTA-3'

-----  
N LSPQ forward and reverse

5'-**TAATACGACTCACTATAGG**GTTTGGTGGACCCTCAGATTCAACTGGCAGTAACCAGAATGGAGAACGCAGTGGGGCCGCATCAAACAACGTCGGCCCCA  
AGGTTTACCAATAAATACTGCGTCTTGGTTCACCGCTCTCACTCAACATGGCAAGGAAGACCTTAAATT-3'  
5'-AATTTAAGGTCCTCTTGGCCATGTTGAGTGAGAGCGGTGAACCAAGACGCAGTATTATGGGTAAACCTTGGGGCCGACGTTGTTTGTATCGCGCCCCAC  
TGCGTTCTCATTCTGTTTACTGCCAGTTGAATCTGAGGGTCCACCAACCCCTATAGTGAGTCGTATTA-3'

-----  
B2M exons 2-3 forward and reverse

5'-**TAATACGACTCACTATAGG**TACTCCAAAGATTTCAGGTTTACTCACGTCATCCAGCAGAGAATGGAAAGTCAAATTTCTGAATTGCTATGTGCTCGGGT  
TTCATCCATCCGACATTGAAGTTGACTTACTGAAGAATGGAGAGAGAATTGAAAAAGTGGAGCATTGCACTTGTCTTTTTCAGCAAGGACTGGTCTTTCTATCT  
CTTGTACTACTACTGAATTCACCCCACTGAAAAAGATGAGTATGCCTGCGGTGTGAACCATGTGACTTTGTACAGCCCAAGATAGTTAAGTGGGATCGAGAC  
ATGTAAGCAGCATCATGGAG-3'  
5'-CTCCATGATGCTGCTTACATGTCTCGATCCCACTTAACTATCTTGGGCTGTGACAAAGTCACATGGTTTACACGGCAGGCATACTCATCTTTTTCAGTGG  
GGGTGAATTCAGTGTAGTACAAGAGATAGAAAGACCAGTCTTGTGTAAGACAAGTCTGAATGCTCCACTTTTTCAATTCTCTCTCCATCTTCTCAGTAAGTC  
AACTTCAATGTCGGATGGATGAAACCCAGACACATAGCAATTCAGGAAATTTGACTTTCCATCTCTGCTGGATGACGTGAGTAAACCTGAATCTTTGGAGTA  
CCCTATAGTGAGTCGTATTA-3'

-----  
Bold sequences indicate T7 promoter sequence that was used for RNA synthesis

Fig. S1 Durand et al.